Explore LGD-4033 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
LGD-4033 (ligandrol) is an oral SARM — a small molecule, not a peptide — sourced in research for muscle and bone studies. It is sold as a research chemical (capsules or an oral liquid), not an approved drug.
LGD-4033 binds the androgen receptor with high affinity and reported tissue selectivity for muscle and bone over prostate and reproductive tissue.[5] It is orally bioavailable with a half-life of ~24–36 hours supporting once-daily dosing. As with all AR agonists, suppression of endogenous LH, FSH, and testosterone is a predictable on-target effect that has been measured directly in the published Phase 1 and Phase 2 trials.[5]
A Phase 1 multiple-ascending-dose trial in healthy young men reported dose-dependent lean body mass gain over 21 days at 0.1–1mg/day with rapid and substantial suppression of LH, FSH, and total testosterone.[5] The Viking VK5211 Phase 2 trial in post-hip-fracture rehabilitation (NCT02578095) reported lean-mass gains at 0.5–2mg/day over 12 weeks but did not show a corresponding improvement in functional endpoints (gait speed, 6-minute walk).[1] As with RAD-140, the hepatology literature has documented drug-induced liver injury (DILI) case reports tied to consumer-grade LGD-4033 use, including severe cholestatic injury in previously healthy young men.[6][7]
Not FDA-approved for any indication. Phase 2 development by Viking Therapeutics did not advance to Phase 3 for the original sarcopenia/hip-fracture indication. FDA warning letters against consumer marketing; WADA-prohibited at all times. Research-grade material only.
LGD-4033 has a reported half-life of ~24–36 hours. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. Long half-life means once-daily dosing accumulates over several days to a steady level — one dose a day is enough to maintain it. Pharmacokinetic source: Basaria et al. J Gerontol 2013 (LGD-4033 phase 1 human PK). It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough LGD-4033 calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.